A growing Barrie-based company has been given the green light by Health Canada to start producing pharmaceutical-grade cannabis. This puts the homegrown organization in a position to supply global demand.
MediPharm Labs in Barrie has been granted a Drug Establishment License, making it the first in the city to have the designation for prescription drug manufacturing. Combined with the company’s existing Cannabis Drug License, it will allow MediPharm to commercially distribute drugs containing cannabis. It will allow the company to supply a growing demand amid an increase in cannabis-based pharmaceutical trials across the globe.
“This truly makes us a full-service pharmaceutical company that can support global pharma’s entry into the drugs containing cannabis space,” explained Keith Strachan, President and Interim CEO, MediPharm Labs. “MediPharm Labs now becomes one of a small number of companies who can take cannabis plant material and produce an API or a pharmaceutical drug product that could have marketing authorization by regulatory bodies such as the European Medicines Agency and FDA.”
Founded in 2015, MediPharm Labs is a pharmaceutical company that specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients and advanced derivative products.
Feature image: Medipharm Labs via Facebook